Kimberley Lilischkis
About Kimberley Lilischkis
Kimberley Lilischkis is the Director of Clinical Operations at BeiGene in Sydney, Australia, with extensive experience in oncology research, clinical operations, and regulatory affairs.
Company
Kimberley Lilischkis is currently working at BeiGene in Sydney, Australia. She joined BeiGene in 2018, initially serving as Associate Director Clinical Operations and was promoted to Director Clinical Operations in 2019. BeiGene is a biotechnology company focused on the development of innovative cancer treatments.
Title
Kimberley Lilischkis holds the title of Director Clinical Operations at BeiGene. In this role, she oversees and coordinates various clinical operations essential to the company's drug development processes.
Background in Clinical Operations
Kimberley Lilischkis has extensive experience in clinical operations, having held various managerial roles within the field. She served as Associate Director Clinical Operations at BeiGene from 2018 to 2019 before being promoted to her current role. Prior to BeiGene, she worked as Clinical and Regulatory Affairs Director at Kazia Therapeutics Limited and held significant positions at The Sydney Children's Hospitals Network, where she accumulated substantial experience in clinical research and management of clinical trials.
Education and Expertise
Kimberley Lilischkis holds a Ph.D. in Cancer Biology from UNSW Australia and a Master of Business Administration (M.B.A.) focused on Technology Management from APESMA/La Trobe University. She also has a Bachelor's Degree in Biochemistry Honours from the University of Sydney. Her strong oncology research background alongside her expertise in Technology Management has equipped her with a unique skill set ideal for clinical operations and regulatory affairs within the biotechnology sector.
Experience in Oncology and Research
Kimberley Lilischkis has a robust background in oncology research, evidenced by her Ph.D. in Cancer Biology. She conducted postdoctoral research at the Max Planck Institute for Medical Research in Germany and Universität Würzburg in Germany. Her experience spans academia, hospital environments, and the biotechnology industry, enriching her perspective on drug development and clinical research.